Literature DB >> 20407604

Extraordinary antigenicity of the human Ro52 autoantigen.

Peter D Burbelo, Kathryn H Ching, Brian L Han, Emily R Bush, Westley H Reeves, Michael J Iadarola.   

Abstract

Autoantibody levels to the SSA complex, composed of Ro52 and Ro60 proteins, are commonly measured in the diagnoses of Sjögren's Syndrome (SjS), as well as other rheumatological diseases. One of these proteins, Ro52, is an interferon-inducible member of the tripartite motif family bearing a RING motif functioning as an E3 ligase that ubiquitinates interferon regulatory factor 8 and other proteins. Using Luciferase Immunoprecipitation Systems (LIPS) we explored the antigenicity of Ro52 in detail. Analysis of antibody responses against Ro52 and 20 other established antigens revealed that Ro52 had the highest antibody titers and most likely represents one of the most immunogenic human proteins. While the antibody titers in many of the SjS patients were significantly and substantially higher than the controls, all healthy individuals had anti-Ro52 autoantibodies. N- and C-terminal fragments of Ro52 showed immunoreactivity in these serum samples, but the sums of these antibody titers were significantly lower than the antibody titers directed against the full-length Ro52. Antibody profiling of controls and SjS patients with three different N-terminal fragments of Ro52 revealed that the coiled-coil region was the most useful diagnostic (66% sensitivity), followed by the B-box (31% sensitivity), and then the RING-finger (24% sensitivity). The C-terminal region of Ro52, containing the B30.2 domain, showed higher antibody titers in SjS patients compared to controls and this region was responsible for the high level of Ro52 immunoreactivity in healthy individuals. Analysis of immunoreactivity to TRIM5, a Ro52-related protein, and the B30.2 domain from BTN1 and pyrin, failed to show significant antibody titers with the control or SjS patient serum. These results highlight the unusually high level of Ro52 antigenicity and demonstrate that autoantibodies are directed at both linear and conformational epitopes spanning the entire molecule.

Entities:  

Keywords:  Autoantibody; Luciferase Immunoprecipitation Systems (LIPS); Sjögren's Syndrome; and Ro52; autoantigen

Year:  2010        PMID: 20407604      PMCID: PMC2855627     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  42 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.

Authors:  Micah T McClain; Latisha D Heinlen; Gregory J Dennis; Jon Roebuck; John B Harley; Judith A James
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

3.  Structural organization and Zn2+-dependent subdomain interactions involving autoantigenic epitopes in the Ring-B-box-coiled-coil (RBCC) region of Ro52.

Authors:  Janosch Hennig; Lars Ottosson; Cecilia Andrésen; Linn Horvath; Vijay K Kuchroo; Klas Broo; Marie Wahren-Herlenius; Maria Sunnerhagen
Journal:  J Biol Chem       Date:  2005-06-17       Impact factor: 5.157

Review 4.  Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays.

Authors:  Edwin Liu; George S Eisenbarth
Journal:  Clin Immunol       Date:  2007-09-27       Impact factor: 3.969

5.  Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells.

Authors:  Ricardo Rajsbaum; Jonathan P Stoye; Anne O'Garra
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

6.  Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein.

Authors:  L Ottosson; S Salomonsson; J Hennig; S-E Sonesson; T Dörner; J Raats; V K Kuchroo; M Sunnerhagen; M Wahren-Herlenius
Journal:  Scand J Immunol       Date:  2005-02       Impact factor: 3.487

7.  Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjögren's syndrome.

Authors:  Lars Ottosson; Janosch Hennig; Alexander Espinosa; Susanna Brauner; Marie Wahren-Herlenius; Maria Sunnerhagen
Journal:  Mol Immunol       Date:  2006-02       Impact factor: 4.407

Review 8.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

9.  A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2.

Authors:  Peter D Burbelo; Hiroki Hirai; Hannah Leahy; Ake Lernmark; Sten A Ivarsson; Michael J Iadarola; Abner Louis Notkins
Journal:  Diabetes Care       Date:  2008-06-05       Impact factor: 19.112

10.  A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins.

Authors:  Peter D Burbelo; Radoslav Goldman; Thomas L Mattson
Journal:  BMC Biotechnol       Date:  2005-08-18       Impact factor: 2.563

View more
  13 in total

Review 1.  Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems.

Authors:  Peter D Burbelo; Kathryn H Ching; Kathleen E Bren; Michael J Iadarola
Journal:  Expert Rev Proteomics       Date:  2011-06       Impact factor: 3.940

2.  Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Authors:  Richard M Yeker; Iago Pinal-Fernandez; Lisa G Rider; Andrew L Mammen; Takayuki Kishi; Katherine Pak; Ira N Targoff; Frederick W Miller
Journal:  Ann Rheum Dis       Date:  2018-01-23       Impact factor: 19.103

3.  Immune response against the coiled coil domain of Sjögren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction.

Authors:  Magdalena Sroka; Harini Bagavant; Indranil Biswas; Abigail Ballard; Umesh S Deshmukh
Journal:  Clin Exp Rheumatol       Date:  2018-01-31       Impact factor: 4.473

4.  Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjogren's Syndrome.

Authors:  K H Ching; P D Burbelo; M Gonzalez-Begne; M E P Roberts; A Coca; I Sanz; M J Iadarola
Journal:  J Dent Res       Date:  2011-01-06       Impact factor: 6.116

Review 5.  New technologies for studying the complexity of oral diseases.

Authors:  P D Burbelo; A Bayat; E E Lebovitz; M J Iadarola
Journal:  Oral Dis       Date:  2011-10-24       Impact factor: 3.511

6.  Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea-pigs.

Authors:  Frank Fabris; Yuankun Yue; Yongxia Qu; Mohamed Chahine; Eric Sobie; Peng Lee; Rosemary Wieczorek; Xian-Cheng Jiang; Pier-Leopoldo Capecchi; Franco Laghi-Pasini; Pietro-Enea Lazzerini; Mohamed Boutjdir
Journal:  J Physiol       Date:  2016-07-26       Impact factor: 5.182

7.  Rapid induction of autoantibodies during ARDS and septic shock.

Authors:  Peter D Burbelo; Nitin Seam; Sandra Groot; Kathryn H Ching; Brian L Han; G Umberto Meduri; Michael J Iadarola; Anthony F Suffredini
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

8.  Two major autoantibody clusters in systemic lupus erythematosus.

Authors:  Kathryn H Ching; Peter D Burbelo; Christopher Tipton; Chungwen Wei; Michelle Petri; Ignacio Sanz; Michael J Iadarola
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

9.  Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor.

Authors:  Emma Chan; Torsten Schaller; Ayad Eddaoudi; Hong Zhan; Choon Ping Tan; Marianne Jacobsen; Adrian J Thrasher; Greg J Towers; Waseem Qasim
Journal:  Hum Gene Ther       Date:  2012-09-26       Impact factor: 5.695

10.  Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases.

Authors:  Maria Infantino; Francesca Meacci; Valentina Grossi; Maurizio Benucci; Gabriella Morozzi; Elio Tonutti; Marilina Tampoia; Antonina Ott; Wolfgang Meyer; Fabiola Atzeni; Piercarlo Sarzi-Puttini; Mariangela Manfredi; Nicola Bizzaro
Journal:  Arthritis Res Ther       Date:  2015-12-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.